Analysis of Amyloid Targeting Antibodies for Alzheimer's Disease Treatment

An analysis of industry-funded trials on Alzheimer's treatments shows that amyloid targeting antibodies do not provide significant benefits and are linked to increased mortality risk, particularly from cerebral hemorrhage. The episode suggests that the high cost of these drugs may not be justified given the risk-benefit ratio.